-transparent.png){kind=logo}
OBJECTIVE Liposomes sterically stabilised with polyethylene glycol (PEG) labelled with technetium-99m were tested for their ability to image adjuvant arthritis in a rat model. METHODS Adjuvant arthritis was induced in the ankle joint of the left hind foot by injection of Mycobacterium butyricum in Freund's incomplete adjuvant in the foot pad. Seven days later animals received the following radiopharmaceuticals labelled with 99mTc (a) non-PEG-liposomes, (b) PEG-liposomes or (c) non-specific human polyclonal IgG. For each of the radiopharmaceuticals the in vivo distribution of the radiolabel was monitored both scintigraphically as well as by counting the dissected tissues at two, eight, and 24 hours after injection. RESULTS The pharmacokinetics of the radiopharmaceuticals differed considerably (halflife in the blood: PEG-liposomes (18 hours) > 99mTc-IgG (3 hours) > non-PEG liposomes (1 hour)). The inflamed focus was visualised with each of the agents. The uptake of each of the radiopharmaceuticals in the inflamed ankle region correlated with their residence time in the blood (inflamed joint uptake: PEG liposomes (1.15% injected dose (ID)/ g) > 99mTc-IgG (0.35% ID/g) > non-PEG-liposomes (0.05% ID/g)). Quantitative analysis of the images showed that the inflamed ankle to background ratio was highest with the PEG-liposomes (7.5 at 24 hours after injection), while with the other two agents this ratio did not exceed 4. CONCLUSIONS This study shows that 99mTc-labelled PEG-liposomes may be an excellent agent to visualise arthritis. Increased label uptake in the inflamed joint and increased target to background ratios can be obtained with PEG-liposomes because of their long circulating properties. In addition to their use as vehicles for scintigraphic imaging of arthritis PEG-liposomes might also be used for the site specific delivery of antirheumatic drugs.
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
April 1987,
Annals of the rheumatic diseases,
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
November 1986,
British medical journal (Clinical research ed.),
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
March 2012,
Equine veterinary journal,
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
July 1979,
British journal of cancer,
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
May 1981,
Journal of medical microbiology,
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
August 1993,
Die Pharmazie,
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
January 1969,
Nordisk medicin,
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
January 1984,
Acta haematologica,
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
January 1996,
Scandinavian journal of rheumatology,
O C Boerman, and
W J Oyen, and
G Storm, and
M L Corvo, and
L van Bloois, and
J W van der Meer, and
F H Corstens
June 1993,
European journal of nuclear medicine,
